News Flashes IGR 18-3

As for many studies in animal models of glaucoma, a key consideration is how generalizable the results are to human glaucoma

Their results support the therapeutic use of NAM in glaucoma; yet, they used NAM doses that are probably not feasible in humans

First, NAM treatment may behave differently in DBA/2J mice and it should be tested in other glaucoma models

Although it can be difficult to compare mouse and human dosing, the equivalent NAM dose in humans would far exceed the lethal concentration

MD and PSD were rather insensitive for detection of progression events

There is a possibility that ODH is associated not only with nighttime BP reduction but also with daytime BP elevation

As with cadaver eyes, flow was found to be segmental with regions of flow and no-flow

The authors also reported pulsatile flow, and dynamic shifts where flow would stop in one region and begin in another

Despite these reported variations between generic formulations, the majority of patients appear to still respond as well as to the branded product, but clinically there are notable exceptions, in terms of efficacy or tolerability.

In-plane tension is the dominant strain component in the lamina.

In a subgroup of severe preoperative inflammation from medication, the addition of preoperative steroids may be still be considered

Travoprost effect seemed to be present during day and night, while the SLT effect was significant only during nighttime

The findings complicate an already-muddy landscape regarding the impact of physical activity on glaucoma.

By examining rates of RNFL change throughout the OCT scan it may be possible to improve accuracy of progression detection

Lens extraction was estimated 67-89% on being cost-effective at three years

A landmark paper reporting the first successful imaging of retinal ganglion cells in the living human eye.

Numerous hurdles remain to be addressed before this remarkable achievement enjoys wide spread implementation.

Issue 18-3

Select Issue